176 related articles for article (PubMed ID: 36473336)
1. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia.
Goh KG; Zakaria MH; Raja Azwan RN; Bhajan Singh KK; Badrul Hisham MH; Hussein Z
Diabetes Metab Syndr; 2023 Jan; 17(1):102680. PubMed ID: 36473336
[TBL] [Abstract][Full Text] [Related]
2. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes.
Shao Y; Lim GJ; Chua CL; Wong YF; Yeoh ECK; Low SKM; Sum CF
Diabetes Res Clin Pract; 2018 Aug; 142():85-91. PubMed ID: 29802956
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting.
Yousuf S; Ahmedani MY
Diabetes Metab Syndr; 2022 Nov; 16(11):102633. PubMed ID: 36279701
[TBL] [Abstract][Full Text] [Related]
4. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi.
Sheikh A; Das B; Sattar S; Islam N
Endocrine; 2023 Apr; 80(1):64-70. PubMed ID: 36580199
[TBL] [Abstract][Full Text] [Related]
5. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes.
Abdelgadir E; Rashid F; Bashier A; Al Saeed M; Khalifa A; Alawadi F; Hassanein M
Diabetes Metab Syndr; 2019; 13(5):2927-2932. PubMed ID: 31425958
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh.
Pathan MDF; Akter N; Selim S; Saifuddin M; Qureshi NK; Kamrul-Hasan ABM; Hannan MA; Ahmed MAU; Mustari M; Chakraborty AK
Diabetes Metab Syndr Obes; 2022; 15():4011-4021. PubMed ID: 36578878
[TBL] [Abstract][Full Text] [Related]
7. A pilot study using flash continuous glucose monitoring in patients with type-2 diabetes on multiple anti-diabetic agents during Ramadan.
Bashir M; Elhadd T; Ali H; Baagar K; Abdel Hakam IA; Al-Mohanadi DHS; Naem E; Al Abdulla A; Mohammed K; Abou-Samra AB
Diabetes Metab Syndr; 2018 Nov; 12(6):965-968. PubMed ID: 29895446
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study.
Ahmed I; Raja UY; Wahab MU; Rehman T; Ishtiaq O; Aamir AH; Ghaffar T; Raza A; Kumar S; Sherin A; Masood F; Randhawa FA; Asghar A; Khan S
BMC Endocr Disord; 2022 Oct; 22(1):247. PubMed ID: 36224542
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan.
Salti I;
Diabet Med; 2009 Dec; 26(12):1255-61. PubMed ID: 20002478
[TBL] [Abstract][Full Text] [Related]
11. Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan.
Gameil MA; Marzouk RE; El-Sebaie AH; Eldeeb AAA
Diabetes Metab Syndr; 2022 Sep; 16(9):102606. PubMed ID: 36063675
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications.
Abdessadek M; Khabbal Y; Magoul R; Marmouzi I; Ajdi F
Ann Pharm Fr; 2019 Sep; 77(5):374-381. PubMed ID: 31255239
[TBL] [Abstract][Full Text] [Related]
13. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan.
Bravis V; Hui E; Salih S; Mehar S; Hassanein M; Devendra D
Diabet Med; 2010 Mar; 27(3):327-31. PubMed ID: 20536496
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
[TBL] [Abstract][Full Text] [Related]
16. Outcome of focused pre-Ramadan education on metabolic and glycaemic parameters in patients with type 2 diabetes mellitus.
El Toony LF; Hamad DA; Omar OM
Diabetes Metab Syndr; 2018 Sep; 12(5):761-767. PubMed ID: 29729978
[TBL] [Abstract][Full Text] [Related]
17. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
[TBL] [Abstract][Full Text] [Related]
18. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study.
Samkari MM; Bokhari NS; Alhajaji R; Ahmed ME; Al Raddadi A; Bahget AK; Saleh SF; Aljehani F; Alzahrani SH; Alsifyani SS; Samkari MM; Badr AF; Alalawi M; Al Sulaiman K
Saudi Pharm J; 2023 Jun; 31(6):972-978. PubMed ID: 37234349
[TBL] [Abstract][Full Text] [Related]
20. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
